Literature DB >> 6386487

Long acting nifedipine in the treatment of severe hypertension.

M Bursztyn, E Grossmann, T Rosenthal.   

Abstract

The medication of patients receiving hydralazine, captopril and minoxidil was replaced by a new galenical form, long-acting nifedipine. An additional decrease in blood pressure was observed in most of the patients. Renal function was maintained in all of them. Adverse reactions may be reduced by the use of long-acting nifedipine, which would permit a reduction in the dosage of captopril and minoxidil.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6386487

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

Review 2.  Mechanism of action of calcium-channel-blocking agents.

Authors:  E Braunwald
Journal:  N Engl J Med       Date:  1982-12-23       Impact factor: 91.245

Review 3.  Calcium antagonists in the treatment of hypertension.

Authors:  A Heidland; E Heidbreder; W H Hörl; R Schäfer
Journal:  Contrib Nephrol       Date:  1982       Impact factor: 1.580

Review 4.  Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.

Authors:  P H Stone; E M Antman; J E Muller; E Braunwald
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

5.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

6.  Acute effects of the calcium antagonist, nifedipine, on blood pressure, pulse rate, and the renin-angiotensin-aldosterone system in patients with essential hypertension.

Authors:  K Hiramatsu; F Yamagishi; T Kubota; T Yamada
Journal:  Am Heart J       Date:  1982-12       Impact factor: 4.749

7.  Interim report of multicenter double-blind, placebo-controlled studies of nifedipine in chronic stable angina.

Authors:  H S Mueller; R A Chahine
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

8.  Nifedipine therapy for coronary-artery spasm. Experience in 127 patients.

Authors:  E Antman; J Muller; S Goldberg; R MacAlpin; M Rubenfire; B Tabatznik; C S Liang; F Heupler; S Achuff; N Reichek; E Geltman; N Z Kerin; R K Neff; E Braunwald
Journal:  N Engl J Med       Date:  1980-06-05       Impact factor: 91.245

9.  Randomized double-blind comparison of nifedipine and isosorbide dinitrate in patients with coronary arterial spasm.

Authors:  J A Hill; R L Feldman; C J Pepine; C R Conti
Journal:  Am J Cardiol       Date:  1982-02-01       Impact factor: 2.778

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
View more
  1 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.